A health care management company's experience with palivizumab.
Silverman
William
W
Horizon/Mercy, 275 Philips Boulevard, Trenton, N.J. 08618, USA.
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000191:economics; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000191:economics; D002986:Clinical Trials as Topic; D017046:Cost Savings; D003362:Cost-Benefit Analysis; D005569:Formularies as Topic; D006279:Health Maintenance Organizations / Q000191:economics / Q000592:standards*; D006801:Humans; D007231:Infant, Newborn; D008484:Medicaid; D009515:New Jersey; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control*; D012307:Risk Factors; D013221:State Health Plans; D014481:United States
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab